Arkolith/Insider Trading/TRIL/Form 4

Uger Robert

Chief Scientific OfficerTrillium Therapeutics Inc. (TRIL) · full profile →Form 4 · filed Apr 9, 2021
Net Selling
Open-Market Buys
$0
Open-Market Sells
$39K
Net Open-Market Flow
-$39K
Transactions
3
2 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Apr 7, 2021Sell(S)4K$10.82$39K0
Apr 7, 2021Option exercise(M)4K$0.30$1K4K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Apr 7, 2021Option exercise(M)4K—$0113K

Transaction Codes

S
Open-market sale
M
Option exercise / conversion

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001062993-21-003543) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML